Navigation Links
ImaRx Therapeutics Reports Business Update and Financial Results for Fourth Quarter and Full Year 2007
Date:3/31/2008

for the funding and continued development of the SonoLysis technology; the Company's efforts to extend the expiration dating on future lots of urokinase; the Company's belief that its labeled inventory will be sufficient to meet market demand through September 2009; Microbix's ability to transfer the urokinase manufacturing process; the Company expect that it will close the transaction with Abbott in the second quarter of 2008; and the Company's belief that it will have sufficient cash resources for at least the next 12 months. These statements are based on management's current expectations and beliefs and are subject to a number of factors and uncertainties that could cause actual results to differ materially from those described in the forward- looking statements. A more complete description of these risks and the event that may cause such events not to occur can be found in the Company's filings with the Securities and Exchange Commission. All information in this press release is as of March 31, 2008, and the Company undertakes no duty to update this information.
. .

ImaRx Therapeutics, Inc.

Consolidated Statements of Operations

(in thousands except share and per share data)

Three Months Ended Year Ended

December 31 December 31

2006 2007 2006 2007

(unaudited)

Revenues:

Product sales, net $226 $2,472 $480 $7,841

Research and development 481 178 848 519

Total operating revenue 707 2,650 1,328 8,360

Costs and expenses:

Cost of product sales 204 989 204 3,518

Research and development 2,589 2,033 9,067 7,424

<
'/>"/>
SOURCE ImaRx Therapeutics, Inc.
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7 8 9 10

Related biology technology :

1. ImaRx Therapeutics Receives Urokinase Lot Release Approval With Extended Expiration Dating
2. ImaRx to Report Corporate Updates and 4Q07 Financial Results
3. ImaRx Reschedules Release of Corporate Updates and Fourth Quarter and Full Year 2007 Financial Results
4. Vicus Therapeutics to Present at the 234th American Chemical Society National Meeting in Boston, MA
5. DJO Incorporateds Pending Merger With ReAble Therapeutics Clears U.S. Antitrust Review
6. PeriCor Therapeutics Announces Closing of Licensing Agreement for Acadesine with Schering-Plough Corporation
7. Systems Medicine (SM), a Subsidiary of Cell Therapeutics, Inc. (CTI), Announces Execution of CRADA with NCI/NIH to Develop Potential Cancer Treatments Targeting the Insulin Growth Factor (IGF) Pathway
8. Amsterdam Molecular Therapeutics to Release H1 2007 Results on August 29, 2007
9. Nektar Therapeutics Appoints Tim Harkness as Chief Financial Officer
10. ExonHit Therapeutics: Allergan and ExonHits First Collaboration Compound to Begin Human Clinical Trials
11. Cell Therapeutics, Inc. Takes Corrective Actions in Response to Nasdaq Determination
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:1/15/2014)... DTS Language Services, Inc . is pleased ... Life Science organizations who need document translations. Clients will ... their documents in advance with a selection of nearly 50 ... often a critical factor in clinical and scientific fields, and ...
(Date:1/15/2014)... Sunnyvale, CA (PRWEB) January 15, 2014 ... throughput research solutions, today announced that Lupin Limited, one ... of Freeslate’s CM Protégé PharmD System for ... in Mumbai, India, is focused on a wide range ...
(Date:1/15/2014)... , Jan. 15, 2014 TaiGen Biotechnology Company, ... exclusive agreement with R-Pharm, a leading Russian pharmaceutical company, ... the Russian Federation , ... Independent States (CIS). Nemonoxacin is a novel antibiotic for the ...
(Date:1/14/2014)... (PRWEB) January 14, 2014 Carahsoft and ... Thursday, January 23, 2014 at 2pm EST (11am PST), ... The topic focuses on how technology can turn raw, ... decisions for government agencies. The online webinar will last ...
Breaking Biology Technology:DTS Improves Efficiency for Life Science Document Translations 2Lupin Selects Freeslate’s CM Protégé PharmD System to Accelerate Polymorph Screening for Drug Development 2Lupin Selects Freeslate’s CM Protégé PharmD System to Accelerate Polymorph Screening for Drug Development 3TaiGen Biotechnology Signed Exclusive License Agreement with R-Pharm for Nemonoxacin (Taigexyn(R)) 2TaiGen Biotechnology Signed Exclusive License Agreement with R-Pharm for Nemonoxacin (Taigexyn(R)) 3TaiGen Biotechnology Signed Exclusive License Agreement with R-Pharm for Nemonoxacin (Taigexyn(R)) 4Webcast - Natural Language Processing: Converting Raw Data into Actionable Knowledge – Hosted by Carahsoft and CDS Federal Services 2
... the rising trend toward miniaturization, carbon nanotubes which ... and possess several unique and very useful properties ... blocks in nanosized electronic and mechanical devices. But it ... tendency to clump together, that make it difficult for ...
... testament to tight integration and ... excellent ... ), a,leader in radiology and medical image and information management solutions,today ... than 100 facilities that use MEDITECH(TM) as their health,information system. AMICAS ...
... device industry to benefit ... trial recruitment efforts, MINNEAPOLIS, May 27 ... has strengthened the,pharmaceutical side of its business with ... a commitment to leveraging differentiators unique,to the medical ...
Cached Biology Technology:Weizmann Institute scientists create new nanotube structures 2AMICAS Announces Integrations at More Than 100 MEDITECH Facilities 2AMICAS Announces Integrations at More Than 100 MEDITECH Facilities 3ThreeWire Expands Presence in the Pharmaceutical Arena 2
(Date:4/24/2014)... --- New research shows that cells are more resilient ... thought. Even when missing critical components, cells can adapt ... way. , In a study published in this week,s ... Michigan State University showed that cells can grow normally ... , "Our genetic information is stored in DNA, which ...
(Date:4/24/2014)... is very pleased to announce that it has assumed ... from the University of Wisconsin. , The ... open-access, peer-reviewed journal that publishes papers on all aspects ... from the molecular to the ecological -- as well ... available to individuals and institutions, and it provides a ...
(Date:4/24/2014)... be improved with new insights into the make-up of ... the Amazon Basin have revealed unprecedented detail of the ... by comparing satellite maps with hundreds of field plots. ... more accurately the amount of carbon each tree can ... schemes, in which trees are given a cash value ...
Breaking Biology News(10 mins):Cell resiliency surprises scientists 2ESA to publish the Journal of Insect Science 2Amazon rainforest survey could improve carbon offset schemes 2
... National Institute of General Medical Sciences, part of the ... Models of Infectious Disease Agent Study for a research ... led by Stephen Eubank, professor. Infectious diseases pose ... worldwide. The Models of Infectious Disease Agent Study (MIDAS) ...
... There might be a time when instead of just drinking ... skin as a way of preventing harmful sun damage or ... caffeine guards against certain skin cancers at the molecular level ... ATR. Scientists believe that based on what they have learned ...
... from NYU Langone Medical Center,s Departments of Orthopaedic Surgery ... used to detect subtle changes in joint cartilage microstructure ... key markers of early osteoarthritis (OA). By using these ... can shift the management of the disease from eventual ...
Cached Biology News:National Institutes of Health renews successful infectious disease research study 2National Institutes of Health renews successful infectious disease research study 3More evidence that caffeine lowers risk of skin cancer 2NYU Langone experts find MRI techniques can detect early osteoarthritis 2
Human Cystatin F MAb (Clone 292103)...
Rat CNTF R alpha Affinity Purified Polyclonal Ab...
... Ac-DEVD-CHO is an inhibitor ... The concentration of inhibitor ... activity must be determined ... Ten micromolar inhibitor is ...
TUNEL Apoptosis Detection Kit...
Biology Products: